Quick answer
Orforglipron is Eli Lilly's oral, small-molecule GLP-1 weight-loss drug — designed to be taken without fasting, unlike the Wegovy tablet. As of June 2026 it is not MHRA-approved, so it is not available from any UK provider. The Wegovy tablet is the approved oral option from £64/month — speak to your prescriber.
Orforglipron UK: what it is, what the trials show, and when it might arrive
Orforglipron is an oral GLP-1 receptor agonist developed by Eli Lilly, the company behind Mounjaro (tirzepatide). Unlike the Wegovy tablet — which is an oral peptide form of semaglutide requiring strict fasting and timing rules — orforglipron is a small-molecule GLP-1 agonist. That distinction matters for how it is taken, how it is absorbed, and potentially how it will be priced.
Status as of June 2026: Orforglipron has not received MHRA approval for use in the UK. It is not available from any UK pharmacy or online clinic.
What makes orforglipron different from the Wegovy tablet
Both are oral GLP-1 drugs, but they work differently at a molecular level:
- Wegovy tablet (oral semaglutide): A peptide-based GLP-1 agonist. Must be taken fasting, 30 minutes before food, with a small amount of water. Absorption is sensitive to food and drink timing.
- Orforglipron: A small-molecule non-peptide GLP-1 agonist. Early trial data suggested it could be taken with or without food, which would remove the fasting restriction that some patients find burdensome.
This flexibility difference, if confirmed for all patients at all doses, could be a meaningful practical advantage for orforglipron once it becomes available.
What the OPAL trials showed
Eli Lilly ran a phase 3 programme called OPAL (Orforglipron for Adults with Obesity or Overweight). The headline results showed:
- Significant body weight reduction vs placebo across multiple dose arms
- Reductions in waist circumference, blood pressure and HbA1c
- Side effect profile broadly consistent with other GLP-1 agonists: nausea, vomiting, diarrhoea — mostly mild to moderate and transient
Full peer-reviewed publications from the OPAL programme are the primary source for efficacy data. As with all GLP-1 trial data, real-world outcomes for individual patients will vary.
FDA approval and US launch
The US Food and Drug Administration (FDA) reviewed the orforglipron new drug application. US regulatory decisions typically precede UK MHRA decisions by several months to over a year, meaning the US launch timeline is the leading indicator for UK availability.
UK MHRA approval timeline
As of June 2026, the MHRA has not approved orforglipron for use in the UK. Eli Lilly has not published a confirmed UK submission or approval date. Based on typical regulatory timelines from US approval to UK approval, the earliest realistic UK availability window is likely to be 2026–2027 — but this is an estimate, not a confirmed date.
We will update this page as soon as MHRA approval or a confirmed UK launch date is announced.
How orforglipron differs from Mounjaro
Both are from Eli Lilly, but they target different mechanisms. Mounjaro (tirzepatide) is a dual GIP and GLP-1 receptor agonist available as a weekly injection in the UK. Orforglipron is a single GLP-1 agonist in oral tablet form. They are separate products with different indications, approval timelines and pricing structures. See our full Wegovy tablet vs orforglipron comparison for a side-by-side breakdown.
Will orforglipron compete with the Wegovy tablet on price?
It is too early to say. Small-molecule drugs are generally cheaper to manufacture than peptide-based drugs, which could influence pricing once the UK market develops. However, launch prices in specialist markets are often not correlated with manufacturing cost, especially in the first year. See our orforglipron price tracker for what we know so far.
How to get notified when orforglipron arrives in the UK
We are tracking all oral GLP-1 drugs including orforglipron as part of our provider tracker. When orforglipron receives MHRA approval and UK providers begin listing it, we will update our tracker and send alerts to subscribers.
Get notified when orforglipron launches in the UK →
Frequently asked questions about orforglipron UK
Is orforglipron available in the UK?
No. As of June 2026, orforglipron has not received MHRA approval. It is not available from any UK pharmacy or online clinic.
Is orforglipron the same as semaglutide?
No. Orforglipron is a small-molecule non-peptide GLP-1 receptor agonist made by Eli Lilly. Semaglutide is a peptide GLP-1 agonist made by Novo Nordisk (sold as Ozempic, Wegovy and the Wegovy tablet). They are different drugs from different companies that both target the GLP-1 receptor.
Can I pre-order orforglipron in the UK?
Not via any GPhC-registered UK provider. Any site currently claiming to sell or pre-order orforglipron in the UK is not a legitimate regulated pharmacy. Do not purchase from unregulated sources.
How does orforglipron compare to the Wegovy tablet?
Both are oral GLP-1 drugs but different molecules with different fasting requirements and different regulatory timelines. The Wegovy tablet is available from UK providers now on a pre-order basis. Orforglipron is not yet available. See our full comparison.
Frequently asked questions
Is orforglipron available in the UK?
No. As of June 2026 orforglipron has no MHRA approval and is not sold by any GPhC-registered UK pharmacy. The Wegovy tablet is the approved oral option, from £64/month.
Is orforglipron the same as semaglutide?
No. Orforglipron is a small-molecule GLP-1 agonist from Eli Lilly; semaglutide is a peptide from Novo Nordisk (Ozempic, Wegovy, Wegovy tablet). Different drugs, same receptor target.
Does orforglipron need fasting like the Wegovy tablet?
Trial data suggest orforglipron can be taken with or without food, unlike the Wegovy tablet's 30-minute fasting rule. This is a potential convenience advantage if it reaches the UK.
How much weight loss does orforglipron cause?
Eli Lilly's Phase 3 trials report meaningful average weight loss, generally lower than the Wegovy tablet on trial averages. Individual results vary. We will publish verified figures as data is confirmed.